Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 1, 2005, Pages 218-223

  Sikkema, Daniel J ^a   Ziembiec, Nancy A ^a   Jones, Thomas R ^a   Hildreth, Stephen W ^a   Madore, Dace V ^a   Quataert, Sally A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SEROTYPING; STANDARDIZATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; CHILD; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 12544256893     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.1.218-223.2005     Document Type: Article

References (49)

1. Amir, J., M. G. Scott, M. H. Nahm, and D. M. Granoff. 1990. Bacteriocidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J. Infect. Dis. 162:163-171.
2. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Kayhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses, and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
3. Artz, A. S., W. B. Ershler, and D. L. Longo. 2003. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16:308-318.
4. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, and K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
5. Bredius, R. G., P. C. Driedijk, M. F. Schouten, R. S. Weening, and T. A. Out. 1992. Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid. Infect. Immun. 60:4838-4847.
6. Bruyn, G. A., B. J. Zegers, and R. van Furth. 1992. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin. Infect. Dis. 14:251-262.
7. Centers for Disease Control and Prevention. 2004. Pneumococcal disease (children). [Online.] http://www.cdc.gov/nip/ed./vpd04pcv-script.pdf.
8. Centers for Disease Control and Prevention. 2004. Pneumococcal disease (adult). [Online.] http://www.cdc.gov/nip/ed./vpd04ppv-script.pdf.
9. Concepcion, N., and C. E. Frasch. 1998. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin. Diagn. Lab. Immunol. 5:199-204.
10. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
11. Dagan, R., H. Kayhty, T. Wuorimaa, M. Yaich, F. Bailleux, O. Zamir, and J. Eskola. 2004. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr. Infect. Dis. J. 23:91-98.
12. Darkes, M. J., and G. L. Plosker. 2002. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr. Drugs 4:609-630.
13. Daum, R. S., D. Hogerman, M. B. Rennels, K. Bewley, F. Malinoski, E. Rothstein, K. Reisinger, S. Block, H. Keyserling, and M. Steinhoff. 1997. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis. 176:445-455.
14. Fedson, D. S., and C. Liss. 2004. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22:927-946.
15. Fedson, D. S., J. A. Scott, and G. Scott. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17(S1):S11-S18.
16. Freijd, A., L. Hammarstrom, M. A. Persson, and C. I. Smith. 1984. Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin. Exp. Immunol. 56:233-238.
17. French, M., and G. Harrison. 1984. Serum IgG subclass concentration in healthy adults: a study using monoclonal antisera. Clin. Exp. Immunol. 56:473-475.
18. Gray B. M., G. M. Converse III, and H. C. Dillon, Jr. 1979. Serotypes of Streptococcus pneumoniae causing disease. J. Infect. Dis. 140:979-983.
19. Hamilton, R. G. 1987. Human IgG subclass measurements in the clinical laboratory. Clin. Chem. 33:1707-1725.
20. Hamilton, R. G. 2001. The human IgG subclasses. [Online.] http://www .emdbiosciences.com/SharedImages/TechnicalLiterature/1_IGGboklet_2001 .pdf.
21. Hausdorff, W. P. 2002. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur. J. Pediatr. 161(S2):S135-S139.
22. Hausdorff, W. P., G. Siber, and P. R. Paradiso. 2001. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357:950-952.
23. Hussain, R., R. W. Poindexter, R. Wistar, and C. B. Reimer. 1986. Use of monoclonal antibodies to quantify subclasses of human IgG. I. Development of two-site immunoenzymometric assays for total IgG subclass determinations. J. Immunol. Methods 93:89-96.
24. Janeway, C. A., P. Travers, M. Walport, and M. Shlomchik. 2001. Immunobiology, 5th ed., p. 141-151. Garland Publishing, New York, N. Y.
25. Jefferis, R., C. B. Reimer, F. Skvaril, G. de Lange, N. R. Ling, J. Lowe, M. R. Walker, D. J. Phillips, C. H. Aloisio, T. W. Wells, J. P. Vaerman, C. G. Magnusson, H. Kubagawa, M. Cooper, F. Vartdal, B. Vandvik, J. J. Haaijman, O. Makela, A. Sarnesto, Z. Lando, J. Gergely, E. Rajnavolgyi, G. Laszlo, J. Radl, and G. A. Molinaro. 1985. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/ W.H.O. collaborative study. Immunol. Lett. 10:223-252.
26. Jodar, L., J. Butler, G. Carlone, R. Dagan, D. Goldblatt, H. Kayhty, K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, and T. Cherian. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
27. Kayhty, H., and H. Ahman. 2001. Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines. Clin. Infect. Dis. 33(S4):S292-S298.
28. Kilpi, T., H. Ahman, J. Jokinen, K. S. Lankinen, A. Palmu, H. Savolainen, M. Gronholm, M. Leinonen, T. Hovi, J. Eskola, H. Kayhty, N. Bohidar, J. C. Sadoff, P. H. Makela, et al. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164.
29. King, J. C., Jr., P. E. Vink, J. J. Farley, M. Parks, M. Smilie, D. Madore, R. Lichenstein, and F. Malinoski. 1996. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 15:192-196.
30. Lottenbach, K. R., C. M. Mink, S. J. Barenkamp, E. L. Andersen, S. M. Homan, and D. C. Powers. 1999. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67:4935-4938.
31. Makela, P. H., and H. Kayhty. 2002. Evolution of conjugate vaccines. Expert Rev. Vaccines 1:399-410.
32. Parkkali, T., H. Kayhty, M. Anttila, T. Ruutu, T. Wuorimaa, A. Soininen, L. Volin, and P. Ruutu. 1999. IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Bone Marrow Transplant. 24:671-678.
33. Posfay-Barbe, K. M., and E. R. Wald. 2004. Pneumococcal vaccines: do they prevent infection and how? Curr. Opin. Infect. Dis. 17:177-184.
34. Quataert, S. A., C. S. Kirch, L. J. Quackenbush Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
35. Quataert, S. A., K. Rittenhouse-Olson, C. S. Kirch, B. Hu, S. Secor, N. Strong, and D. V. Madore. 2004. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(F). Clin. Diagn. Lab. Immunol. 11:1064-1069.
36. Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. S. Reisinger, D. A. Hogerman, D. V. Madore, I. Chang, P. R. Paradiso, F. J. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611.
37. Seppala, I., H. Sarvas, O. Makela, P. Mattila, J. Eskola, and H. Kayhty. 1988. Human antibody responses to two conjugate vaccines of Haemophilus influenzae type B saccharides and diphtheria toxin. Scand. J. Immunol. 28: 471-479.
38. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
39. Soininen, A., M. Karpala, S. L. Wahlman, K. Lehtonen, and H. Kayhty. 2002. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin. Diagn. Lab. Immunol. 9:1032-1038.
40. Soininen, A., H. Kayhty, I. Seppala, and T. Wuorimaa. 1998. Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF. Clin. Diagn. Lab. Immunol. 5:561-566.
41. Soininen, A., I. Seppala, T. Nieminen, J. Eskola, and H. Kayhty. 1999. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17:1889-1897.
42. Soininen, A., G. van den Dobbelsteen, L. Oomen, and H. Kayhty. 2000. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific? Clin. Diagn. Lab. Immunol. 7:468-476.
43. Ursinger, W. R., and A. H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370.
44. Wernette, C. M., C. E. Frasch, D. V. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, H. Kayhty, I. Jonsdottir, and M. H. Nahm. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
45. Whitney, C. G., M. M. Parley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, A. Schuchat, et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
46. World Health Organization. 2004. Streptococcus pneumoniae. [Online.] http://www.who.int/vaccine_research/documents/new_vaccines/en/print /html.
47. Wuorimaa, T., R. Dagan, M. Vakevainen, F. Bailleux, R. Haikala, M. Yaich, J. Eskola, and H. Kayhty. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211-1215.
48. Yu, X., Y. Sun, C. Frasch, N. Concepcion, and N. H. Moon. 1999. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin. Diagn. Lab. Immunol. 6:519-524.
49. Zangwill, K. M., C. M. Vadheim, A. M. Vannier, L. S. Hemenway, D. P. Greenberg, and J. I. Ward. 1996. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J. Infect. Dis. 174:752-759.